Orforglipron Intermediate;(S)-Orforglipron Carboxylic Acid Intermediate;GLP-1 Agonist API Intermediate (Indole-Oxadiazole Core)
CAS:2212021-83-3
Chemical Formula:C22H25N3O5
Molecular Weight:411.46
Availability: R&D; Commercialization
⬤ CAS No.2212021-83-3
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | 5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid |
| CAS No. | 2212021-83-3 |
| Chemical Formula | C22H25N3O5 |
| Molecular Weight | 411.46 |
| Related Categories | Orforglipron Intermediate |
| Density | 1.48±0.1 g/cm3(Predicted) |
| Acidity coefficient (pKa) | 4.55±0.30(Predicted) |
| InChIKey | VWANSYGDVGYGTG-ODJFAWIYNA-N |
| Note | This product is specifically used as a chemical synthesis intermediate for orforglipron and other GLP-1 receptor agonist drugs and is not suitable for direct drug preparation or clinical use. |
| Core drug synthesis | Our product is a key intermediate of Orforglipron and is mainly used for: synthesize GLP-1 receptor agonist drugs, targeted treatment of type 2 diabetes and obesity. |
| R&D and extended applications | As a structural template for optimizing the activity and pharmacokinetic properties of GLP-1 analogs. |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Comparing Nifedipine & Amlodipine: Onset, duration, and side effects decoded. Demand for amlodipine intermediates? We deliver quality.
Hechi Vice Mayor Chen Zhijie toured Tianming Pharmaceutical’s facilities, praising its R&D strength and the “Jinan R&D + Hechi production” model.
This non-peptide GLP-1 receptor agonist, now in late-stage clinical trials, is redefining possibilities for diabetes and obesity treatment. Let’s unpack what makes it distinctive from both lab bench and manufacturing perspectives.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
